Human post-mortem AD brain tissues have shown significant reductions in PGC-1α mRNA as a function of clinical AD progression [59] and levels are also lower in Huntington's disease, and PGC-1α has been shown to be protective in models of HD and PD [60–65]. Here, PPARGC1A is linked to juvenile Huntington disease.